Switching to ustekinumab in children with Crohn's disease or ulcerative colitis and psoriasis
Follows gut health in children switched to ustekinumab after anti-TNF caused psoriasis.
Plain-language title generated from the registry record
Registry title: Digestive Evolution of Children With Crohn's Disease or Ulcerative Colitis Whose Anti-TNFα Treatment Was Switched to Ustekinumab Due to Paradoxical Psoriasis,
Key facts
- Where
- Nice, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children with Crohn's disease or ulcerative colitis who stopped an anti-TNFα drug because of severe paradoxical psoriasis and then received ustekinumab.
- Age
- Registry lists 6 to 17 years; the criteria say under 19 years.
- Sex
- All sexes can join.
- Disease stage
- Confirmed inflammatory bowel disease (Crohn's disease or ulcerative colitis). Severe paradoxical psoriasis, diagnosed by a dermatologist, that did not respond to usual treatments (topical or systemic).
- Earlier treatment
- Must have received an anti-TNFα for at least 3 months, stopped it because of the psoriasis, and then received ustekinumab in its place.
Main reasons for not taking part
- Diagnosis of inflammatory bowel disease not confirmed
- Anti-TNFα stopped for a reason other than psoriasis
- Patient older than 18 years
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 17 years old?
Source: NCT07529236, who can take part
Where in France
- CHU de NiceNice, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Centre Hospitalier Universitaire de Nice
- Trial code
- NCT07529236
- Record updated
- 25 June 2026
- Original description
Inflammatory bowel diseases (IBD) include Crohn's disease (CD) and ulcerative colitis (UC). They cause abdominal pain and chronic diarrhea and/or rectal bleeding, which can lead to weight loss and malnutrition. IBD affects people of all ages but usually appears before the age of 30, most often between the ages of 14 and 24. Childhood IBD is generally considered to be more progressive than adult IBD. Although there is no cure for IBD, many medications can help reduce inflammation and relieve IBD symptoms. Anti-TNF drugs (infliximab and adalimumab) are used early in high-risk patients or when standard treatments have failed. Cutaneous side effects are common in pediatrics (>10%), primarily psoriasiform eruptions (41%), often exudative, affecting skin folds and scalp, recurrent skin infections (20%), and eczematous eruptions (10%). Only 5% of patients need to discontinue treatment due to these side effects. In such cases, the recommended treatment is ustekinumab (European guidelines). While this treatment has been described as effective in patients who have failed anti-TNFα therapy, little data is available on the gastrointestinal and dermatological outcomes of patients on anti-TNFα therapy who switch to ustekinumab for dermatological reasons.Read full original descriptionShow less
Digestive Evolution of Children With Crohn's Disease or Ulcerative Colitis Whose Anti-TNFα Was Switched to Ustekinumab Due to Paradoxical Psoriasis: Real Life Data
Inflammatory bowel diseases (IBD) include Crohn's disease (CD) and ulcerative colitis (UC). They cause abdominal pain and chronic diarrhea and/or rectal bleeding, which can lead to weight loss and malnutrition. IBD affects people of all ages but usually appears before the age of 30, most often between the ages of 14 and 24. Childhood IBD is generally considered to be more progressive than adult IBD. Although there is no cure for IBD, many medications can help reduce inflammation and relieve IBD symptoms. Anti-TNF drugs (infliximab and adalimumab) are used early in high-risk patients or when standard treatments have failed. Cutaneous side effects are common in pediatrics (>10%), primarily psoriasiform eruptions (41%), often exudative, affecting skin folds and scalp, recurrent skin infections (20%), and eczematous eruptions (10%). Only 5% of patients need to discontinue treatment due to these side effects. In such cases, the recommended treatment is ustekinumab (European guidelines). While this treatment has been described as effective in patients who have failed anti-TNFα therapy, little data is available on the gastrointestinal and dermatological outcomes of patients on anti-TNFα therapy who switch to ustekinumab for dermatological reasons.
Inclusion: Patients capable of giving their non-opposition; Patient <19 years; Diagnosis of IBD established; Having received an anti-TNFα for IBD for at least 3 months; Having stopped the anti-TNFα for a severe paradoxical psoriasis resistant to usual treatments (topical or systemic) diagnosed by a dermatologist; Having received Ustekinumab in relay of the anti-TNFα.
Exclusion: Patient > 18 years; Diagnosis of IBD not confirmed; Discontinuation of anti-TNFα for a cause other than psoriasis.